Searchable abstracts of presentations at key conferences in endocrinology

ea0031p168 | Neoplasia, cancer and late effects | SFEBES2013

Review of patients with adrenocortical carcinoma at a tertiary referral centre

Deshpande S , Parker V , Ahmed U , Moore D , Jamieson N V , Gurnell M G , Chatterjee V K , Basu B , Corrie P , Simpson H L

Introduction: Adrenocortical carcinoma (ACC) is a rare but devastating malignancy. We performed a review to determine outcome in our patient cohort.Of 20 patients 14 were females, six males. Median overall survival was 27.5 months (range 1–168), nine being deceased. Mean age at presentation 52.3 years (range 18–71). The majority of cancers were large; 5% ≤5 cm, 40% 5–10 cm, 55 >10 cm. 25% had stage IV disease, 10% stage III, 55% ...

ea0031p263 | Pituitary | SFEBES2013

11C-methionine PET–CT co-registered with volume MRI identifies residual functioning tumour in acromegaly

Koulouri Olympia , Kandasamy Narayanan , Moran Carla , Chatterjee Krish , Halsall David , Cheow HK , Antoun Nagui , Hoole Andrew , Burnet Neil , Donnelly Neil , Mannion Richard , Pickard John , Gurnell Mark

Although MRI remains the investigation of choice for pituitary imaging, it does not reliably identify all secretory microadenomas, and cannot always discriminate residual tumour from post-surgical change following hypophysectomy. We hypothesised that i) imaging with the PET ligand 11C-methionine, which is taken up at sites of peptide/protein synthesis, would permit more reliable identification of functioning pituitary adenoma, and ii) co-registration of PET–CT ...

ea0015p152 | Diabetes, metabolism and cardiovascular | SFEBES2008

Weight gain, on the background of human PPARγ haploinsufficiency, exposes a metabolic phenotype

Mitchell Catherine , Al-Ali Nadia , Savage David , Simpson Helen , Luan Jian'an , Semple Robert , Agostini Maura , Wareham Nicholas , Gurnell Mark , O'Rahilly Stephen , Chatterjee V Krishna

Peroxisome proliferator activated receptor gamma (PPARγ), a ligand-inducible transcription factor, is essential for adipocyte differentiation and lipogenesis. We previously described a kindred in which some individuals were heterozygous for a frameshift/premature stop mutation, (A553ΔAAAiT)fs.185(stop186) in PPARγ, with the truncated protein being non-functional and lacking dominant negative activity1. PPARγ null heterozygotes had norm...

ea0011p361 | Diabetes, metabolism and cardiovascular | ECE2006

Insulin receptoropathies are distinguished from other syndromes of severe insulin resistance by elevated plasma adiponectin levels

Semple RK , Soos MA , Mitchell CM , Wilson JC , Luan J , Cochran EK , Wareham NJ , Gorden P , Chatterjee VKK , O’Rahilly S

Leptin and adiponectin are cytokine-like hormones secreted by white adipose tissue. Plasma leptin correlates closely with total body fat mass, and its secretion is positively regulated by insulin in vivo and in vitro. Hypoleptinaemia is a key centrally-mediated orexigenic stimulus. Plasma adiponectin, in contrast, correlates negatively with whole body fat mass and insulin resistance in adults, and its expression is regulated negatively by insulin in vivo a...

ea0002p37 | Endocrine tumours and neoplasia | SFE2001

Minimally invasive parathyroid surgery with intra-operative PTH measurement: an economical approach to the management of primary hyperparathyroidism

Gurnell E , Poultsidis A , McFarlane I , Sarkar A , Curran S , Hitchcock M , Munday I , Raggatt P , Balan K , Edwards O , Wishart G , Chatterjee V

BACKGROUND: Primary hyperparathyroidism (HPT) is increasingly diagnosed, particularly in an older population. Recent studies indicate improvement in bone mineral density (BMD) and psychological wellbeing even following treatment of apparent asymptomatic disease, supporting a lower threshold for surgical intervention. With disease being due to a solitary adenoma in most (83%) cases, we have utilised preoperative imaging together with intra-operative parathyroid hormone (IOPTH) ...

ea0092ps2-11-02 | Miscellaneous 2 | ETA2023

Resistance to thyroid hormone alpha: outcomes of twelve years of thyroxine therapy

Moran Carla , Vargha-Khadem Faraneh , Clark Chris , Seunarine Kiran , Muntoni Francesco , Bethlehem Richard , Lindley Keith , Watson Laura , Lyons Greta , Dattani Mehul T. , Chatterjee Krishna

Objectives: In 2011, we described the first case of Resistance to Thyroid Hormone due to a mutation in thyroid hormone receptor a (RTHα) in a six year old child with features of congenital hypothyroidism but near-normal thyroid function tests. Here, we report outcomes following twelve years of thyroxine therapy in this patient.Methods: Colonic contractility, intestinal transit time, growth, resting energy expenditure, heart rate and biochemical para...

ea0078oc4.3 | Oral Communications 4 | BSPED2021

Growth hormone receptor 6Ω pseudoexon activation: a novel cause of severe growth hormone insensitivity

Cottrell Emily , Maharaj Avinaash , Williams Jack , Chatterjee Sumana , Cirillo Grazia , del Giudice Emanuele Miraglia , Festa Adalgisa , Palumbo Stefania , Capalbo Donatella , Salerno Mariacarolina , Pignata Claudio , Savage Martin O. , Schilbach Katharina , Bidlingmaier Martin , Hwa Vivian , Metherell Louise A. , Grandone Anna , Helen L. Storr

Context: Severe or ‘classical’ growth hormone insensitivity (GHI) is characterised by extreme short stature, dysmorphism and metabolic anomalies. It is caused by homozygous or compound heterozygous mutations of the Growth Hormone Receptor gene (GHR). Genetic analysis traditionally focuses on the exonic regions of gene(s). The non-coding regions of the genome may harbour numerous disease-causing mutations that are not well recognised or understood.<p clas...

ea0089c33 | Clinical – Surgery/Applied Pathology | NANETS2022

High-Grade Pancreatic Neuroendocrine Neoplasms: Interobserver Diagnostic Accuracy and Relationship with Clinicopathological and Molecular Characteristics

Taherian, MD Mehran , Waters, MD Rebecca , Foo, MD Wai Chin , Maru, MD Dipen , Abraham, MD Susan C. , Rashid, MBBS, PhD Asif , Wang, MD, PhD Huamin , Wei, MD Dongguang , Taggart, MD Melissa W. , Chatterjee, MD Deyali

Background: The pathogenesis, biologic behavior, and treatment of well-differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC) are different. The diagnosis relies on multiple factors, but pathologic assessment is crucial. Based on currently available diagnostic criteria, the distinction between NET G3 and NEC are made on morphologic assessment, without taking Ki-67 proliferative index into consideration. This study looks at the conc...

ea0038p299 | Pituitary | SFEBES2015

A role for 11C-methionine PET/CT–MRI in the management of de novo and residual acromegaly

Koulouri Olympia , Hoole Andrew , Steuwe Andrea , Gillett Daniel , Powlson Andrew , Akker Scott , Aylwin Simon , Brooke Antonia , Buch Harit , Drake Will , Levy Miles , Siddiqi Ayesha , Simpson Helen , Chatterjee Krishna , Burnet Neil , Antoun Nagui , Cheow Heok , Mannion Richard , Pickard John , Gurnell Mark

Background: Although MRI remains the investigation of choice for pituitary imaging, it does not provide information about the ‘functionality’ of lesions (e.g. residual adenoma vs post-surgical scar tissue), and cannot reliably identify all microadenomas. These limitations are of particular relevance in acromegaly where clinical and biochemical evidence of disease activity mandates (further) treatment.Methods: We hypothesised that i) imaging wit...

ea0058oc5.8 | Oral Communications 5 | BSPED2018

Patients with short stature and GH/IGF-1 insensitivity harbour copy number variants causing a Silver-Russell-like phenotype

Cottrell Emily , Chatterjee Sumana , Moore Gudrun , Ishida Miho , Greening James , Wright Neil , Bossowski Artur , Deeb Asma , Al Basiri Iman , Rose Stephen , Mason Avril , Ahn JooWook , Bint Susan , Savage Martin O , Metherell Louise A , Storr Helen L

Introduction: Our Centre receives international referrals for genetic analysis of children with short stature (SS) and features of GH/IGF-1 insensitivity. Copy number variation (CNV) hasn’t previously been investigated in GH/IGF-1 insensitivity. We hypothesised CNVs contribute to the phenotype in our undiagnosed cohort.Experimental design/methodology: CGH was performed with oligonucleotide array using ~60,000 probes in 60 patients (38 M, mean age 7....